Shanghai Vitalgen BioPharma Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-32
RECRUITING0
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| VGN-R09b injection NCT06432140 |
P2/3 | Active, not recruiting | Aromatic L-amino Acid Decarboxylase Deficiency | 13 | 2026-07-23 (+2 mo) |
| VGN-R09b NCT06480461 |
P1/2 | Active, not recruiting | Parkinson's Disease | 39 | 2026-09-10 (-10 mo) |
| VGR-R01 NCT06699108 |
P3 | Active, not recruiting | Bietti Crystalline Dystrophy; Inherited Retinal Diseases | 45 | 2026-12-01 |
| VGR-R01 NCT07586306 |
P1/2 | Not yet recruiting | Bietti Crystalline Dystrophy | 15 | 2027-07-31 |
| VGN-R08b 4.2×10^13 vg NCT07414290 |
P1/2 | Not yet recruiting | Parkinson Disease (PD) | 17 | 2027-09-01 |
| VGN-R08b NCT07603050 |
P1/2 | Not yet recruiting | Gaucher Disease Type 3 | 12 | 2028-05-29 |